Attached files
file | filename |
---|---|
EX-99.2 - Emmaus Life Sciences, Inc. | v164529_ex99-2.htm |
EX-99.3 - Emmaus Life Sciences, Inc. | v164529_ex99-3.htm |
EX-99.1 - Emmaus Life Sciences, Inc. | v164529_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): November 2,
2009
CNS
RESPONSE, INC.
(Exact
name of Company as specified in its charter)
Delaware
|
0-26285
|
87-0419387
|
||
(State
or other
jurisdiction
of
incorporation)
|
(Commission
File No.)
|
(I.R.S.
Employer
Identification
No.)
|
2755
Bristol Street, Suite 285
Costa
Mesa, CA 92626
(Address
of principal executive offices)
(714)
545-3288
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other
Events.
On
November 3, 2009, CNS Response, Inc. (the “Company”) issued a press release
reporting the results of a study presented by Charles DeBattista, D.M.H, M.D.,
at the U.S. Psychiatric and Mental Health Congress. A copy of the
press release is included as Exhibit 99.1 to this Form 8-K and is incorporated
herein by reference. A copy of the poster presented by Dr. DeBattista
on November 2, 2009 at the U.S. Psychiatric and Mental Health Congress is
included as Exhibit 99.2 to this Form 8-K and is incorporated herein by
reference.
The
Company will be holding a conference call to discuss the top-line results of its
recently completed study. CNS stockholders are encouraged to participate in the
conference call, which will be held today at 8:00 a.m. PST. Please call Suzanne
Schnitzer at 949.553.9748 to register for the call. You will be given the
toll-free dial-in number and access code to the conference call, along with the
login instructions to join the simultaneous web conference. A copy of
the materials to be presented by the Company over the web are included as
Exhibit 99.3 to this Form 8-K and are incorporated herein by
reference.
Item
9.01 Financial
Statements and Exhibits.
(d) Exhibits
The
following exhibits are filed herewith:
99.1
|
Press
Release Issued November 3, 2009.
|
99.2
|
Copy
of poster presented at U.S. Psychiatric and Mental Health
Congress.
|
99.3
|
Copy
of web presentation
materials.
|
SIGNATURES
Pursuant
to the Securities Exchange Act of 1934, as amended, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
CNS
Response, Inc.
|
||
By:
|
/s/
George Carpenter
|
|
November
3, 2009
|
George
Carpenter
|
|
Chief
Executive Officer
|
Exhibit
Index
99.1
|
Press
Release Issued November 3, 2009.
|
99.2
|
Copy
of poster presented at U.S. Psychiatric and Mental Health
Congress.
|
99.3
|
Copy
of web presentation
materials.
|